Thioredoxin 2 (Trx2) is a mitochondrial-specific antioxidant enzyme belonging to the thioredoxin family, which plays a critical role in maintaining cellular redox homeostasis. It contains a conserved dithiol active site (Cys-Gly-Pro-Cys) that enables it to reduce oxidized substrates, thereby neutralizing reactive oxygen species (ROS) and protecting mitochondrial components from oxidative damage. Trx2 is essential for regulating apoptosis by interacting with apoptosis signal-regulating kinase 1 (ASK1) and inhibiting its pro-apoptotic activity. It also supports mitochondrial DNA synthesis and repair, energy metabolism, and cell survival under stress conditions. Dysregulation of Trx2 has been implicated in various pathologies, including neurodegenerative diseases, cardiovascular disorders, cancer, and diabetes.
Antibodies targeting Trx2 are vital tools for studying its expression, localization, and function in both physiological and disease contexts. These antibodies enable detection of Trx2 via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of mitochondrial oxidative stress mechanisms. Specific Trx2 antibodies are often validated for cross-reactivity across species (e.g., human, mouse, rat) and tested for sensitivity to ensure accurate quantification. Research utilizing Trx2 antibodies has provided insights into its role in aging, metabolic syndromes, and therapeutic responses to redox-targeting drugs. Their application continues to advance understanding of mitochondrial biology and oxidative stress-related pathways.